Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06708429 · ClinicalTrials.gov registry record
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
A clinical trial of Lynch Syndrome and Hereditary Cancer Syndrome, sponsored by San Raffaele University.
- Recruiting
- Registry status
- 300
- Enrollment target
- 5
- Study locations
NCT06708429 is a study of Lynch Syndrome and Hereditary Cancer Syndrome that is actively recruiting participants, run by San Raffaele University. The registered enrollment target is 300 participants, below the 2,302-participant average among 21 other Lynch Syndrome trials with a reported enrollment target (87% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT06708429, a study of Lynch Syndrome and Hereditary Cancer Syndrome, is actively recruiting participants, sponsored by San Raffaele University.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 5
- Study locations
Study Summary
Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals. It increases the lifetime risk of colorectal and endometrial cancer primarily, but it is associated with a high risk of other cancers (pancreas, stomach, ovarian, central nervous system, skin, among others). It is caused by a germline mutation in one of four DNA mismatch repair genes or a terminal deletion of the MSH2-adjacent gene EpCAM. Despite adherence to cancer surveillance programs, many patients still develop colorectal cancer and endometrial cancer. The Prospective Lynch Syndrome Database (PLSD) suggests that more frequent surveillance intervals do not significantly improve cancer risk reduction. The PLSD also revealed that the incidence of colorectal cancer in MLH1 and MSH2 carriers was even higher than previously expected, reaching as high as 41-36% among MLH1 carriers, regardless of ethnic background. The development of colorectal cancer despite surveillance is an unresolved question. Therefore, there is an unmet need for effective cancer prevention strategies.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
Study Locations (5)
California
- Beckman Research Institute at City of Hope - Monrovia
Lombardy
- Gastronterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Hospital - Milan
MI
- Dipartimento di Chirurgia Oncologica e Dipartimento di Oncologia Sperimentale Istituto Nazionale Tumori - Milan
PM
- Dipartimento di controllo qualità e rischio chimico biologico, AOOR Villa Sofia Cervello - Palermo
Other
- Chirurgia Generale, Azienda Ospedaliero Universitaria di Cagliari - Cagliari
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2034-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06708429
The ClinicalTrials.gov registry entry for NCT06708429 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,302-participant average among 21 other Lynch Syndrome trials with a reported enrollment target (87% lower). The listed sponsor is San Raffaele University, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Lynch Syndrome appearing as the primary indexed condition, and to 1 intervention - of which LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System) is the first listed.
NCT06708429 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Lombardy, MI.
Frequently Asked Questions
What is clinical trial NCT06708429 about?
NCT06708429 is a clinical study titled "Lynch Syndrome X-Talk of Enteral Mucosa With Immune System". Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals. It increases the lifetime risk of colorectal and endometrial cancer primarily, but it is associated with a high risk of other cancers (pancreas, stomach...
What is the current status of trial NCT06708429?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2023-06-01. Estimated completion is 2034-06-01.
What conditions does trial NCT06708429 study?
This clinical trial studies the following conditions: Lynch Syndrome, Hereditary Cancer Syndrome, Hereditary Cancer, MLH1 Gene Mutation, HNPCC.
What interventions are being tested in trial NCT06708429?
The interventions under investigation include: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06708429?
This trial is sponsored by San Raffaele University, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06708429 being conducted?
This trial has 5 study locations across California, Lombardy, MI, PM. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lynch Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Cancer of the Pancreas Screening-5 CAPS5)Study
RECRUITING · Phase 3
-
Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients
RECRUITING
-
Lynch Syndrome Integrative Epidemiology and Genetics
RECRUITING
-
A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome
RECRUITING · Phase 2
-
Identifying and Caring for Individuals With Inherited Cancer Syndrome
RECRUITING · NA
-
A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.